Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis

Background: Bronchiectasis is a chronic inflammation of the bronchi with recurrent infections and hemoptysis. The MAGELLAN study compared oral rivaroxaban, 10 mg once daily (QD), for 35 ± 4 days with subcutaneous enoxaparin 40 mg QD for 10 ± 4 days followed by placebo for 25 ± 4 days to prevent veno...

Full description

Bibliographic Details
Main Authors: Concetta Lipardi MD, PhD, C. Gregory Elliott MD, Chiara L. Sugarmann BSN, MSHS, Lloyd Haskell MD, Alex C. Spyropoulos MD, Gary E. Raskob PhD, Jianfeng Xu PhD, Wentao Lu PhD, Jessica Marsigliano BS, Theodore Spiro MD, Zhong Yuan MD, PhD, Shujian Wu MD, PhD, Elliot S. Barnathan MD
Format: Article
Language:English
Published: SAGE Publishing 2021-10-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/10760296211053316

Internet

https://doi.org/10.1177/10760296211053316

Similar Items